Cough Suppressant Drugs Market To Surpass US$ 1518.8 Mn Threshold By 2026 - Coherent Market Insights

The Global CoughSuppressant Drugs Market, by Disease Type (Dry Cough and Wet Cough), byDrug Type (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate,Pholcodine, and Others), by Product Type (Over-the-counter (OTC) andPrescription Drug), by Age Group (Pediatric and Adult), by Dosage Form (Syrup,Tablet, and Others), by Distribution Channel (Hospital, Retail Pharmacy, OnlinePharmacy, and Others), and by Region (North America, Latin America, Europe,Asia Pacific, Middle East, and Africa), was valued at US$ 1100.4 Mn in 2017 andis projected to exhibit a CAGR of 3.7% during the forecast period (2018–2026).

Frequent approvals and launch ofnew cough suppressant drugs is expected to drive the global cough suppressantdrugs market growth over the forecast period. For instance, in 2017, AurobindoPharma Limited received the U.S. Food & Drug Administration (FDA) approvalfor its Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets,600/30 mg and 1200/60mg (OTC) indicated to loosen mucus and phlegm, and thinout bronchial secretions, making coughs more productive. Aurobindo’sGuaifenesin and Dextromethorphan Hydrobromide extended-release tablets are thegeneric equivalent of Reckitt Benckiser’s Mucinex DM tablets. Such approval andlaunch of new cough suppressant drugs in the market is expected to drive theglobal cough suppressant drugs market growth over the forecast period.

Browse 42 Market Data Tables and40 Figures spread through 175 Pages and in-depth TOC on Global CoughSuppressant Drugs Market, by Disease Type (Dry Cough and Wet Cough), by DrugType (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate,Pholcodine, and Others), by Product Type (Over-the-counter (OTC) andPrescription Drug), by Age Group (Pediatric and Adult), by Dosage Form (Syrup,Tablet, and Others), by Distribution Channel (Hospital, Retail Pharmacy, OnlinePharmacy, and Others), and Region (North America, Latin America, Europe, AsiaPacific, Middle East, and Africa) - Global Forecast to 2026.

* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2427

Some stringent regulationsagainst the use of cough suppressant drugs is expected to hinder the globaldrug suppressant drugs market growth over the forecast period. For instance, inJanuary 2018, FDA introduced a regulation, which inhibits the use ofcodeine-based cough suppressant drugs in children less than 18 years of age. InAugust 2018, the Colorado introduced a law, which prohibits the sales ofover-the-counter (OTC) medicines containing the cough suppressantdextromethorphan (DXM) to minors and in 2017, Health Canada proposed to bannon-prescription cough suppressant drug codeine sales in 2017. Such regulationsthat limits the sales and adoption of cough suppressant drugs is expected toaffect the market growth.

Key Takeaways of the CoughSuppressant Drugs Market:

The global cough suppressantdrugs market is expected to exhibit a CAGR of 3.7% during the forecast period(2018 – 2026), owing to frequent product launches and approvals, and robustpipeline of novel cough suppressant drugs

Key players in the market areadopting strategies such as mergers and partnership for the development,manufacturing, and marketing of new cough suppressant drugs. For instance, in2012, Vernalis plc, a U.K.-based development stage pharmaceutical company, andTris Pharma Inc., a U.S.-based specialty pharmaceutical company, entered intoan exclusive license agreement for the development and commercialization ofmultiple novel products focused on the U.S. prescription cough/cold market.

Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/cough-suppressant-drugs-market-2427

Approval and launch of new coughsuppressant drugs in the U.S. is expected to drive growth of the North Americacough suppressant drugs market during the forecast period

Asia Pacific cough suppressantdrugs market is expected to show good growth over the forecast period, owing tohigh prevalence of cough in countries such as India and China. For instance,according to the data published by Journal of the Association of Physicians ofIndia in 2016, it was estimated that around 54% of the population in Indiasuffers from cough

Major players operating in theglobal cough suppressant drugs market include Perrigo Company plc, Vernalisplc. Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., AcellaPharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd.,Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2427

AboutCoherent Market Insights:            

CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.

ContactUs:

mailto:sales@coherentmarketinsights.com

U.S.Office:

Name:  Mr. Shah

CoherentMarket Insights 1001 4th Ave,

# 3200Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN:  +050-5539-1737